Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tdap vaccine
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Tdap-Swedish Institute for Infectious Disease Control-tetanus-diphtheria-pertussis refers to the Tdap (tetanus, reduced-dose diphtheria, and acellular pertussis) booster vaccines evaluated by the Swedish Institute for Infectious Disease Control (SMI) in clinical trials, specifically as a school-leaving booster for adolescents. The primary vaccines studied in this context include Td5ap (COVAXiS), a five-component acellular pertussis vaccine, and Td1aP (diTekiBooster), a one-component acellular pertussis vaccine. These vaccines are designed to reinforce immunity against *Clostridium tetani*, *Corynebacterium diphtheriae*, and *Bordetella pertussis*. The mechanism of action involves the induction of neutralizing antibodies against tetanus and diphtheria toxins, as well as immune responses against pertussis antigens such as pertussis toxoid, filamentous hemagglutinin, pertactin, and fimbriae. These vaccines are typically administered via intramuscular injection and are adsorbed onto aluminum salts to enhance immunogenicity.
- Brand names
- COVAXiSdiTekiBooster
- Other names
- Tetanus-diphtheria-acellular pertussis vaccineTdap booster
02
Targets
Diphtheria toxinFHA (Filamentous hemagglutinin)PRN (Pertactin)T1F (Type 1 fimbriae)
Beyond the preview
Go deeper on Tdap vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tdap vaccine.